Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States

Diagnostic Microbiology and Infectious Disease

Volumn 33, Issue 4, 1999, Pages 217-222

  Pfaller, M A ^a   Messer, S A ^a   Hollis, R J ^a   Jones, R N ^a   Doern, G V ^a   Brandt, M E ^b   Hajjeh, R A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; UNITED STATES;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE; UNITED STATES;

EID: 0033037324     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00160-6     Document Type: Article

References (25)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128.
2. Boschman C.R., Bodnar U.R., Tornatore M.A., Obias A.A., Noskin G.A., Englund K., Postelnick M.A., Sariano T., Peterson L.R. Thirteen-years evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother. 42:1998;734-738.
3. Fridkin S.K., Jarvis W.R. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 9:1996;499-511.
4. Ghannoum M.A., Rex J.H., Galgiani J.H. Susceptibility testing of fungi current status of the correlation of in vitro data with clinical outcome . J Clin Microbiol. 34:1996;489-495.
5. National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-A. Wayne, PA: NCCLS.
6. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., Wagener M.M., Rinaldi M.G., Yu V.L. The changing face of candidemia Emergence of non-Candida albicans species and antifungal resistance . Am J Med. 100:1996;617-623.
7. Pfaller M.A. Nosocomial candidiasis emerging species, reservoirs, and modes of transmission . Clin Infect Dis. 22:(Suppl 2):1996;S89-S94.
8. Pfaller M.A. The epidemiology of invasive mycoses narrowing the gap . Clin Infect Dis. 27:1998;1148-1150.
9. Pfaller M.A., Rhine-Chalberg J., Redding S.W., Smith J., Farinacci G., Fothergill A.W., Rinaldi M.G. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 32:1994;59-64.
10. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to Candida albicans frequency of occurrence and antifungal susceptibility in the SCOPE Program . Diagn Microbiol Infect Dis. 31:1998;327-332.
11. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans frequency of occurrence and antifungal susceptibility in the SCOPE Program . Diagn Microbiol Infect Dis. 30:1998;121-129.
12. SENTRY Participant Group , Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Hollis R.J., Messer S.A. International surveillance of blood stream infections due to Candida species frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program . J Clin Microbiol. 36:1998;1886-1889.
13. Pfaller M.A., Messer S.A., Houston A., et al. National Epidemiology of Mycoses Survey A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species . Diagn Microbiol Infect Dis. 31:1998;289-296.
14. Pfaller M.A., Lockhart S.R., Pujol C., Swails-Wenger J.A., Messer S.A., Edmond M.B., Jones R.N., Wenzel R.P., Soll D.R. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans blood stream isolates. J Clin Microbiol. 36:1998;1518-1529.
15. Powderly W.G. Resistant candidiasis. AIDS Res Hum Retroviruses. 10:1994;925-929.
16. Price M.F., LaRocco M.T., Gentry L.O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 38:1994;1422-1424.
17. Rees J.R., Pinner R.W., Hajjeh R.A., Brandt M.E., Reingold A.L. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993 results of a population-based laboratory active surveillance . Clin Infect Dis. 27:1998;1138-1147.
18. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 39:1995;1-8.
19. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., Webb C.D. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother. 39:1995;40-44.
20. Rex J.H., Pfaller M.A., Galgiani N.J., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Rinaldi M.G., Walsh T.J., Barry A.L. Development of interpretive breakpoints for antifungal susceptibility testing Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections . Clin Infect Dis. 24:1997;235-247.
21. Warren N.G., Hazen K.C. Candida, Cryptococcus, and other yeasts of medical importance. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H., Manual of Clinical Microbiology. 1995;723-737 American Society for Microbiology, Washington, DC.
22. Wardle H.M., Law D., Moore C.B., Mason C., Denning D.W. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother. 39:1995;868-871.
23. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 20:1995;115-125.
24. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 325:1991;1274-1315.
25. Wingard J.R., Merz W.G., Rinaldi M.G., Miller C.B., Karp J.E., Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 27:1993;1847-1849.